Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Gene therapy could prevent breast cancer from spreading

26 September 2016

By Ebtehal Moussa

Appeared in BioNews 870

A new gene therapy technique using microRNAs has successfully prevented the spread of breast cancer in mice.

It is hoped that by preventing breast cancer from spreading through the metastasis of cancer cells, survival rates could be dramatically improved.

'Death rates from breast cancer remain high and relatively unchanged despite advances in medicine and technology. We wanted to find a way to stop metastasis from happening altogether. It is the turning point, where survival rates drop exponentially,' said Dr Noam Shomron of the Sackler School of Medicine, Tel Aviv, who carried out the study jointly with researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts.

MicroRNAs are short strands of RNA that regulate gene expression, acting as master switches that control the activity of genes. The researchers had already identified two microRNAs – miR-96 and miR-182 – which control the expression of the protein palladin, which appears to promote breast cancer metastasis.

To deliver the treatment to the tumour cells, they embedded the nanoparticles containing the microRNAs into a hydrogel scaffold, and implanted this into the mouse tumours. This resulted in a dramatic reduction in breast cancer metastasis: 'We have stopped the spread of breast cancer in mice – zero metastatic sites in the lungs, liver and brain, and in every other organ we tested,' said Dr Shomron in a video.

The research was published in the journal Nature Communications and was carried out on mice with triple negative breast cancer – the most aggressive subtype. When the researchers added the chemotherapy drug cisplatin to the implant, the treatment was even more effective, reducing the size of the primary tumour as well as preventing its metastasis.

'We believe local delivery is much more effective [than systemic treatment] because it gives us a much higher effective dose of the cargo – in this case the two microRNAs and the cisplatin,' said Dr Natalie Artzi of MIT, who led the research.

'We are very excited about the results so far, and the efficacy seems to be really good. So the next step will be to move on to larger models and then to clinical trials, although there is still a long way to go,' she added.

SOURCES & REFERENCES
MIT (press release) | 19 September 2016
 
Nature Communications | 19 September 2016
 
UPI | 19 September 2016
 
Tel Aviv University (press release) | 20 September 2016
 
Haaretz | 20 September 2016
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

24 April 2017 - by Dr James Heather 
Researchers have discovered a new approach to slow the rate of breast cancer tumour growth in mice...
16 January 2017 - by Dr Loredana Guglielmi 
Researchers have identified 23 genes that are linked to metastasis – the spread of cancer cells to other parts of the body...

30 August 2016 - by Ebtehal Moussa 
A new genetic test could predict which patients with early-stage breast cancer patients would benefit from chemotherapy...
22 August 2016 - by Ebtehal Moussa 
Researchers in the UK have discovered two key genes capable of predicting 10-year disease-specific survival outcomes in breast cancer patients...
15 February 2016 - by Helen Robertson 
A blood test to diagnose common types of cancer is in development after researchers found that five forms of the disease share a telltale chemical signature...
02 November 2015 - by Dr Jess Buxton 
A recent study suggests that embryonic gene activity may be altered by factors present in the womb even before implantation. This finding triggered a somewhat misleading newspaper article entitled 'Infertile mums "pass on DNA"', which claimed the research means recipients of donor eggs are passing on their own DNA to their child. This isn't the case...
22 April 2013 - by Siobhan Chan 
Scientists have identified an eight-gene 'signature' that can predict patients' response to chemotherapy...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation